More USP: Third Instrument Qualification Stimuli published for Comments
More EMA/CHMP: New Active Substance Guideline? Concept Paper published for Comments
More GDP Non-Compliance Report: No GDP conform Quality System
More GDP Non-Compliance Report: No WDA without Responsible Person
More FDA Requirements for the "Worst Case" Product during Cleaning Validation
More ANVISA´s Q&A on Medical Cannabis for Clinical Investigations
More Pharmaceutical Industry: FDA Data on the Level of Quality
More FDA's recommended Font and Font Size for Instructions for Use Labeling
More USP General Chapter <621> Chromatography: Delay of the Implementation of Two New Requirements